MOTS-c (10mg) – Mitochondrial-Derived Peptide (MDP)

MOTS-C is a short peptide that researchers have studied with growing interest since it was first described in the early 2010s. The name stands for "mitochondrial open reading frame of the twelve S rRNA type-c," which is a long way of saying that the genetic instructions for this peptide are not stored in the cell nucleus like most peptides. Instead, those instructions sit inside the mitochondrion — the tiny structure inside each cell that turns nutrients into usable energy. That single detail is what makes MOTS-C unusual and is part of why it has attracted so much attention in peptide research.

For many decades, the mitochondrion was thought of mainly as a power plant. It produced energy in the form of adenosine triphosphate (ATP) and largely kept to itself. The discovery of MOTS-C, along with a small group of related peptides sometimes called mitochondrial-derived peptides, changed that picture. It suggested that the mitochondrion is also a source of biological signals that can travel out into the rest of the cell and, in laboratory observations, even into the bloodstream. That re-framing has opened up many new questions for the peptide research community.

Researchers have explored MOTS-C in the context of how cells handle stress, how they process sugars and fats, and how their internal energy systems respond when nutrients or oxygen are limited. Studies have investigated whether the peptide's levels change with age and with exercise in animal models. Scientific literature has examined a possible connection between mitochondrial peptides and the broader field of metabolic research. None of this work establishes that MOTS-C does any particular thing in a person, and none of it should be read as a medical claim. The peptide remains a research compound studied in laboratory and analytical settings only.

This page is a long-form educational overview written in plain English. It walks through what MOTS-C is, how it was discovered, what the published science currently describes about its role inside the cell, how its molecular structure is laid out, and where ongoing research interest sits today. It also explains how MOTS-C differs from other peptides that often get mentioned alongside it, defines the most useful technical terms, and answers common questions that arrive from students, curious readers, and laboratory staff who encounter the compound for the first time.

MOTS-C is a peptide. A peptide is a short chain of amino acids — the same kinds of building blocks that make up larger proteins. Where the line sits between "peptide" and "protein" is a question of length and convention. MOTS-C is firmly in peptide territory because it is only sixteen amino acids long. By comparison, a typical protein in the human body might contain hundreds of amino acids and fold into complex three-dimensional shapes. MOTS-C is much smaller and much simpler.

What sets MOTS-C apart from most other peptides is where its genetic code lives. The cell nucleus contains the bulk of the genome, and almost every peptide and protein the body produces is read from a gene stored there. Mitochondria, however, carry their own small piece of DNA — a leftover from their evolutionary origin as free-living bacteria that were absorbed into early cells billions of years ago. This mitochondrial DNA is best known for coding a handful of components used inside the mitochondrion itself. The discovery that it also produces small signaling peptides such as MOTS-C, humanin, and the SHLP family was unexpected.

The peptide is encoded within a short open reading frame inside the twelve S ribosomal RNA gene of the mitochondrion. That overlap between a ribosomal RNA gene and a protein-coding sequence is unusual in cellular biology. Researchers refer to peptides made this way as mitochondrial-derived peptides, or MDPs. MOTS-C is the best-studied member of this group after humanin.

In laboratory work, MOTS-C is typically produced through chemical synthesis rather than extracted from cells. Solid-phase peptide synthesis allows scientists to assemble the sixteen amino acids in the correct order using automated machinery, then purify the result using techniques such as reversed-phase high-performance liquid chromatography (HPLC). The resulting material is usually supplied as a lyophilized — meaning freeze-dried — powder that can be reconstituted for analytical work.

The peptide is classified in scientific literature as a mitochondrial-derived peptide and, more broadly, as a metabolic signaling molecule. That second classification reflects the fact that most of the research has focused on its possible role in how cells sense and respond to changes in fuel availability. It is not a hormone in the traditional sense, but it shares some characteristics with hormones in the way it is released and the way it appears to influence cells at a distance from where it is produced.

It is worth pausing on what MOTS-C is not. It is not a steroid, not a growth factor in the conventional sense, and not a member of the growth-hormone-secretagogue family that includes peptides like Ipamorelin or CJC-1295. It is also not a member of the GLP-1 incretin family that includes Tirzepatide and Retatrutide. Those families have different origins, different receptors, and different research histories. Lumping all peptides together is a common point of confusion, and the answer in MOTS-C's case is simply that it sits in its own small and relatively new category.

Finally, MOTS-C is an active area of scientific exploration rather than a settled chapter in a textbook. The published literature is still relatively young, the experimental tools used to measure it are still being refined, and several aspects of how it works — including which receptor or receptors it interacts with — remain open questions. That is part of why it is interesting to peptide researchers and part of why this overview avoids any definitive claims about what the peptide does outside of the laboratory.

The story of MOTS-C begins with a broader scientific question: do mitochondria do more than just generate energy? For most of the twentieth century the answer was effectively "not much else worth noting." The mitochondrion was treated as a power plant with its own small backup genome, and that genome was thought to code only for a handful of structural proteins and RNAs needed for the organelle's internal machinery.

That picture began to shift in 2003, when humanin — another short peptide encoded inside the mitochondrial sixteen S ribosomal RNA gene — was identified by a research team studying cellular stress responses. Humanin was the first widely recognized mitochondrial-derived peptide, and its discovery hinted that the mitochondrial genome might be doing more biological work than anyone had assumed. It took several more years before additional members of this peptide family were described.

MOTS-C was reported in 2015 by researchers at the University of Southern California, led by Pinchas Cohen and Changhan Lee. They used computational scanning of the mitochondrial twelve S ribosomal RNA gene to look for small open reading frames that might encode functional peptides. One of those open reading frames produced the sixteen-amino-acid sequence that became known as MOTS-C. The initial publication described the peptide's existence, its synthesis route in laboratory conditions, and a set of early experiments in animal models that suggested it had some involvement in metabolic signaling.

That first paper triggered a wave of follow-up studies. Some research groups focused on confirming the peptide's existence in different tissues and species. Others explored how its levels might change in response to stresses such as fasting, exercise, or high-fat feeding in animal models. Still others used biochemical and cell-culture systems to look at which signaling pathways inside the cell appeared to be influenced when MOTS-C was applied to laboratory samples. None of these studies established a clinical role for the peptide, but together they began to build the outline of a research story.

By the late 2010s, several scientific milestones had been reached. Investigators reported on changes in measured mitochondrial-derived peptide levels with age in animal models. Other publications examined the relationship between MOTS-C and the AMPK pathway, a well-known cellular fuel-sensing system. Reviews in metabolic research journals began including mitochondrial-derived peptides as a small but recognized topic alongside more established areas of energy biology. Conferences focused on peptide science and on mitochondrial biology began featuring dedicated sessions on MDPs.

Key publications in this evolving literature include the original 2015 paper introducing MOTS-C in Cell Metabolism, subsequent reviews examining the broader mitochondrial-derived peptide family, and a growing number of mechanistic studies that explore specific signaling pathways. Several research groups have also explored MOTS-C in the context of skeletal muscle biology and exercise physiology in animal models, contributing to ongoing scientific interest in how the peptide might fit into the larger picture of cellular energy management.

In parallel with academic work, MOTS-C entered the catalog of compounds available through specialty chemical and peptide synthesis suppliers. This availability allowed laboratory groups outside the original discovery teams to run their own experiments, replicate findings, and explore new questions. The growth of the research literature has tracked closely with the growth in availability of high-purity synthetic material.

The history of MOTS-C is, in many ways, still being written. The peptide is just over a decade old as a recognized subject in published science. By comparison, peptides like insulin have a research history of more than a century. Anyone studying MOTS-C should expect both the experimental toolkit and the explanatory models around it to keep evolving as new work appears.

To understand why MOTS-C has held the attention of peptide researchers, it helps to step back and look at how cells handle energy. Every cell in the body needs a continuous supply of ATP — the small chemical energy currency that powers nearly every active process from muscle contraction to thinking. Mitochondria are the main producers of ATP. They take in nutrients that have been broken down from food, combine them with oxygen, and release the energy stored in their chemical bonds in a form the cell can use.

This process is tightly regulated. Cells need to match energy production to energy demand and to the availability of fuel. When fuel is plentiful, mitochondria can run their normal pathways. When fuel is scarce, when oxygen is limited, or when the cell is under other forms of stress, the cell needs to adjust. It can do this in many ways: by switching the fuel it prefers, by changing how many mitochondria it has, by altering how those mitochondria are structured, or by triggering broader programs of gene expression that change the cell's overall behavior.

A central player in this regulation is AMP-activated protein kinase, almost always shortened to AMPK. AMPK is sometimes called the cell's fuel gauge. When ATP levels drop and a related molecule called AMP rises, AMPK becomes active. Once active, it switches on processes that generate more ATP — including the breakdown of fats and the uptake of glucose into cells — and it tones down processes that consume ATP without producing it.

• MOTS-C is studied in the context of mitochondrial energy biology rather than as a hormone with a single defined target.
• AMPK is the most frequently cited pathway in published MOTS-C research.
• Most mechanistic data comes from cell-culture and animal-model studies, not from human clinical trials.
• The peptide's precise receptor and uptake mechanism remain open scientific questions.

At the molecular level, MOTS-C is a sixteen-amino-acid peptide with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, often written in single-letter code as MRWQEMGYIFYPRKLR. That sequence is short enough to be assembled reliably through solid-phase peptide synthesis and short enough that high-purity material can be characterized using standard analytical techniques.

The peptide does not fold into a complex three-dimensional structure the way a large protein does. Short linear peptides like MOTS-C typically exist as flexible chains in solution, sampling many conformations rather than locking into a single rigid shape. That flexibility is part of why mapping its interactions with cellular partners has been challenging — there is no obvious binding pocket to study.

Stability is an important consideration for any peptide used in research. Because MOTS-C contains methionine residues, which are vulnerable to oxidation, and because linear peptides in general are sensitive to enzymatic breakdown, careful handling matters. Lyophilized material stored at appropriate freezer temperatures is generally considered stable for extended periods, while reconstituted solutions are far less stable and need to be used or refrozen promptly.

Manufacturing-quality material is typically produced by solid-phase peptide synthesis, then purified by reversed-phase HPLC to reach research-grade purity. Identity is usually confirmed by mass spectrometry, and purity is reported as an HPLC percentage. A Certificate of Analysis from the manufacturer documents these values and is the standard way to verify the material before any laboratory use.

Storage considerations for the lyophilized form generally include keeping the vial sealed, away from light, and at deep-freeze temperatures until needed. Once reconstituted into a buffer solution, the peptide's stability drops sharply, and most laboratory protocols recommend either using the solution quickly or aliquoting it into smaller portions and refreezing to avoid repeated freeze-thaw cycles. These are general laboratory handling principles rather than instructions for any other use.

Researchers have explored MOTS-C across a broader set of scientific themes than any short summary can fully capture, but several core areas of interest have emerged in the published literature. None of the areas below represent established therapeutic uses, and none should be read as suggesting clinical benefit. They are research directions — open questions that laboratories around the world are working to clarify.

• Cell-culture studies of metabolic signaling
• Animal-model investigations of mitochondrial biology
• Computational modeling of peptide-protein interactions
• Stability and analytical characterization of synthetic material
• Method development for accurate measurement of endogenous peptide levels

MOTS-C is frequently grouped with other peptides in casual conversation, but those groupings can be misleading. The compounds that get mentioned alongside it generally come from very different biological families, and their research contexts are not interchangeable. Below is a short comparison meant to clarify where MOTS-C sits relative to other compounds that researchers and curious readers commonly ask about.

The clearest immediate comparison is with other mitochondrial-derived peptides. Humanin was identified more than a decade before MOTS-C and is the most-studied member of the MDP family. Like MOTS-C, it is encoded inside the mitochondrial genome rather than the nuclear genome. Unlike MOTS-C, humanin has been studied more heavily in the context of cellular stress and neuroprotection in laboratory models. The SHLP peptides — small humanin-like peptides — represent a smaller, less-characterized branch of the same family.

Outside the MDP family, MOTS-C is sometimes mentioned alongside metabolic-research compounds such as 5-Amino-1MQ, NAD precursors, and other mitochondrially focused molecules. These are not peptides in the same sense as MOTS-C; they are small molecules or nucleotides with their own distinct mechanisms. They share an interest in mitochondrial biology with MOTS-C but do not share the same molecular family or research history.

Peptides such as BPC-157 and TB-500 are sometimes lumped together with MOTS-C in informal writing about "research peptides," but the science is very different. BPC-157 and TB-500 are studied primarily in tissue-repair research contexts; their amino-acid sequences, origins, and mechanisms have little overlap with MOTS-C. Similarly, GLP-1 family compounds such as Tirzepatide and Retatrutide are studied in incretin and metabolic biology contexts that, while adjacent to MOTS-C's broad metabolic focus, involve very different pathways and receptors.

A short comparison table is below. It is intended to highlight differences, not to rank compounds. Each entry has its own scientific literature, its own research history, and its own laboratory considerations.

The scientific story of MOTS-C is best understood as a still-emerging chapter in mitochondrial biology rather than a fixed body of established facts. When the peptide was first described in 2015, the dominant view of mitochondrial output was still relatively narrow. The discovery that the mitochondrion produces a small set of biologically active peptides — including humanin earlier and MOTS-C alongside it — pushed researchers to expand their picture of what mitochondria contribute to whole-cell biology.

A major theme in the research literature is how MOTS-C intersects with AMP-activated protein kinase. Multiple laboratories have reported observations in cultured cells and animal-model tissues that suggest the peptide influences activity in this pathway. Because AMPK sits at the center of how cells balance fuel use, the implication has been that MOTS-C might function as part of the broader system the cell uses to sense and adjust to its energy state. The exact molecular handshake — whether MOTS-C activates AMPK directly, whether it influences upstream regulators, or whether the effect is indirect through changes in metabolite levels — is still being investigated.

A second theme involves the concept of retrograde signaling. Conventional thinking treats the cell nucleus as the command center and mitochondria as the workforce. The discovery of mitochondrial-derived peptides has helped support the alternative idea that mitochondria send signals back to the nucleus, influencing decisions about gene expression and broader cellular state. MOTS-C has been used as one example in scientific discussions of how this back-channel might operate.

A third theme is the relationship between MOTS-C and physiological stressors observed in animal models. Studies have reported changes in measured peptide levels in response to fasting, exercise, and high-fat feeding. Researchers have explored how chronic versus acute stress affects mitochondrial peptide production, and whether the patterns observed line up with what is already known about mitochondrial adaptation in muscle and other energy-demanding tissues. These observations remain animal-model and laboratory findings; they have not produced clinical conclusions and should not be read as suggesting any direct human application.

A fourth theme is aging biology. Some published work has reported declines in measured MOTS-C levels with age in animal models, and a body of secondary commentary has discussed how this might relate to broader patterns of mitochondrial decline observed with aging. This is one of the more speculative areas of MOTS-C research and one where it is especially important not to overstate what the data show.

Beyond these themes, there are smaller and more specialized areas of investigation. Some research groups have explored how MOTS-C behaves in liver, kidney, and adipose tissue models. Others have looked at how its production might be regulated at the level of the mitochondrial genome itself. Still others have focused on analytical methods — finding ways to measure the peptide reliably in complex biological samples, which is a technical challenge for any low-abundance signaling molecule.

Emerging questions in the field include the identification of a specific receptor or receptors that mediate MOTS-C signaling, the role of post-translational modifications such as oxidation of methionine residues, the interaction between MOTS-C and other mitochondrial-derived peptides like humanin, and the broader physiological significance of the MDP family across species. There are also methodological questions: how to harmonize measurement protocols between laboratories, how to validate antibodies and assays used to detect the peptide, and how to design experiments that distinguish direct effects of the peptide from indirect consequences of its administration to laboratory systems.

Reviews of the field generally conclude that MOTS-C is an interesting and growing topic in mitochondrial biology, that significant mechanistic uncertainty remains, and that the next decade of work will likely either consolidate the current picture or revise it substantially. For students, hobbyist readers, and laboratory staff encountering MOTS-C for the first time, the most accurate framing is that of a genuinely active research area where careful reading of primary literature beats reliance on simplified summaries.

MOTS-C is a sixteen-amino-acid peptide that comes from an unusual place — the mitochondrial genome — and that has attracted growing attention in peptide research since it was first described in 2015. As a member of the small mitochondrial-derived peptide family, it sits at the intersection of cell biology, biochemistry, and metabolic research. It is studied primarily in cell-culture and animal-model systems, with much of the published work focused on its possible role in the AMPK pathway, in cellular stress responses, and in the broader question of how mitochondria communicate with the rest of the cell.

The peptide attracts scientific interest for several reasons. Its origin inside the mitochondrion challenges older textbook descriptions of where biological signals come from. Its connection to fuel-sensing pathways places it in a research neighborhood that includes some of the most heavily studied questions in cell biology. Its presence in measurable amounts in blood from animal models has made it a candidate for studies of broader physiological signaling. And the relative youth of the field — only a decade of formal study — means there is more open ground than settled ground in the literature, which itself is attractive to researchers looking for productive questions to work on.

The most important educational takeaways from this overview are straightforward. MOTS-C is a research compound, not a medicine, supplement, or treatment. The available scientific literature is largely preclinical and continues to evolve. Statements about what the peptide does should be treated as descriptions of laboratory observations rather than as claims about effects in people. Anyone reading further about MOTS-C should weigh primary scientific sources, recognize where the field genuinely agrees and where it does not, and treat speculative summaries with appropriate skepticism.

For students, science-curious readers, and laboratory staff encountering MOTS-C for the first time, this page is meant to provide a grounded starting point. From here, the broader literature on mitochondrial biology, mitochondrial-derived peptides, AMPK signaling, and cellular energy metabolism offers many directions for deeper reading. MOTS-C will likely continue to be a meaningful part of those conversations as new work appears, and the way its story is told will continue to evolve along with the science.